Sign in

Catherine

Research Analyst at Citizens

Catherine Cusimano is the Director for Energy Infrastructure Credit at Nuveen, specializing in private credit and control equity transactions within the energy and infrastructure sectors. She has covered companies involved in energy, power, and renewables, and has a performance track record built from her experience at HPS Investment Partners and Bernhard Capital Partners, where she focused on middle-market services and infrastructure private equity investments. Catherine began her analyst career as an Associate E&P Equity Analyst for Capital One Securities, advancing to Vice President at HPS, Principal at BCP, and joining Nuveen in 2025. She holds a cum laude BSM in Finance and Economics and a Master of Management in Energy Finance and Trading from Tulane University.

Catherine's questions to KalVista Pharmaceuticals (KALV) leadership

Catherine's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

Catherine asked about the number of scripts and patients that contributed to the $1.4 million in revenue reported for July and inquired about the exact date ECTERLEET became commercially available in July following its approval.

Answer

Ben Palleiko, CEO, stated that ECTERLEET became available roughly 10 days after approval, with the first start forms received on the day of approval, predating actual shipments. Ryan Baker, Head of Investor Relations, clarified that revenue is recognized when the product is received by specialty pharmacies, in accordance with ASC 606, with a subsequent lag until it reaches patients.

Ask Fintool Equity Research AI

Catherine's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

Catherine asked about the number of scripts and patients that contributed to the reported $1.4 million in revenue for July, and when EKTERLY became commercially available following its approval.

Answer

Ben Palleiko, CEO, stated that EKTERLY became available approximately 10 days after approval, with patient start forms beginning on the day of approval. Brian Piekos, CFO, clarified that revenue is recognized when the product is received by specialty pharmacies, in accordance with ASC 606, with a subsequent lag until it reaches patients.

Ask Fintool Equity Research AI